Lexeo Therapeutics (NASDAQ:LXEO) Insider Sells $34,758.72 in Stock

Key Points

• Lexeo Therapeutics insider Tai Sandi See sold 3,888 shares for a total of $34,758.72, a 5.57% decrease in ownership, leaving him with 65,862 shares valued at approximately $588,806.28.
• Lexeo Therapeutics stock rose by 9.2%, trading at $9.58, with a significant increase in trading volume compared to its average.
• The company reported earnings of ($0.60) EPS for the last quarter, beating estimates, and analysts predict the company will post -3.14 EPS for the current fiscal year.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) insider Tai Sandi See sold 3,888 shares of the business's stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $34,758.72. Following the completion of the sale, the insider owned 65,862 shares in the company, valued at $588,806.28. The trade was a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Tai Sandi See also recently made the following trade(s):

• On Monday, August 18th, Tai Sandi See sold 382 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $4.67, for a total transaction of $1,783.94.

Lexeo Therapeutics Stock Up 9.2%

Shares of LXEO stock traded up $0.81 during trading hours on Friday, reaching $9.58. 4,078,215 shares of the stock traded hands, compared to its average volume of 1,387,014. Lexeo Therapeutics, Inc. has a 1-year low of $1.45 and a 1-year high of $11.72. The business has a fifty day moving average price of $5.91 and a 200 day moving average price of $4.39. The firm has a market capitalization of $517.32 million, a PE ratio of -2.94 and a beta of 1.66.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.04. Research analysts expect that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. CWM LLC increased its stake in Lexeo Therapeutics by 150.3% in the 2nd quarter. CWM LLC now owns 10,351 shares of the company's stock valued at $42,000 after buying an additional 6,216 shares during the period. Ethic Inc. acquired a new position in shares of Lexeo Therapeutics during the 2nd quarter worth $44,000. Cerity Partners LLC acquired a new position in shares of Lexeo Therapeutics during the 2nd quarter worth $50,000. Intech Investment Management LLC increased its stake in shares of Lexeo Therapeutics by 20.7% during the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company's stock worth $55,000 after purchasing an additional 2,342 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Lexeo Therapeutics during the 2nd quarter worth $60,000. Institutional investors and hedge funds own 60.67% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on LXEO shares. Oppenheimer started coverage on shares of Lexeo Therapeutics in a report on Thursday, July 31st. They set an "outperform" rating and a $20.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Lexeo Therapeutics in a report on Wednesday, October 8th. Chardan Capital boosted their price target on shares of Lexeo Therapeutics from $15.00 to $17.00 and gave the company a "buy" rating in a report on Tuesday, October 7th. Leerink Partners upped their price objective on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the company an "outperform" rating in a research note on Tuesday, October 7th. Finally, Guggenheim assumed coverage on shares of Lexeo Therapeutics in a research note on Wednesday. They issued a "buy" rating and a $30.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.86.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.